Efficacy of Pioglitazone on Bone Metabolism in Postmenopausal Women With Impaired Fasting Glucose.

Inclusion Criteria: * Is female and has not experienced menses for at least 5 years. * Has a Fasting Plasma Glucose level greater than or equal to 100 and less than 126 mg/dL or a 2-hour post-oral glucose tolerance test greater than or equal to 140 and less than or equal to 199 mg/dL at Screening. * Has a body mass index greater than or equal to 16 and less than or equal to 40 kg/m2 and weighs less than 300 pounds (approximately 136 kilograms). * Agrees to take daily supplements of Vitamin D (a minimum of 800 IU daily) and calcium (a minimum of 1000 mg daily) during the treatment and wash-out periods. * Has clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis \[fasted for at least 8 hours\]) within the reference range for the testing laboratory unless the results are deemed not clinically significant by the investigator or sponsor. * Is in good health as determined by the physician (ie, via medical history and physical examination) at Screening. Exclusion Criteria: * Has a fasting triglyceride level greater than 500 mg/dL. * Has a hemoglobinopathy causing anemia or interfering with glycosylated hemoglobin assays. * Has an alanine transaminase level greater than or equal to 2.5 times the upper limit of normal, active liver disease or jaundice. * Has Vitamin D (25-OH-D) less than 20 ng/mL. * Has Baseline Bone Mineral Density defined as a T-score less than -2.0 at the total hip, spine, or femoral neck based on Caucasian reference values. * Has unexplained microscopic or macroscopic hematuria confirmed by repeat testing. * Has any of the following disorders: * Rheumatoid Arthritis * Thyroid (uncontrolled on thyroid replacement therapy), parathyroid, pituitary, nutritional, inflammatory, gastrointestinal, autoimmune, or renal or other disease known to affect bone metabolism. * A personal history of kidney stones. * Has a clinical history after age 45 of wrist, hip, or leg fractures. * Has a history of more than 1 asymptomatic vertebral deformity or any vertebral deformity attributed to osteoporosis. * Has a known history of drug abuse (defined as illicit drug use) or a known history of alcohol abuse within 2 years of Screening. * Has signs and/or symptoms of heart failure. * Is currently participating in another investigational study or has participated in an investigational study within the past 30 days or 5 half lives of the investigational product, whichever is longer. * Has any other serious disease or condition at screening or at randomization that might make it difficult to successfully manage and follow up with the subject according to the protocol. * Has a history of cancer, other than basal cell carcinoma or Stage 1 squamous cell carcinoma of the skin that has not been in remission for at least 5 years prior to the first dose of study drug. * Has a history of breast cancer. * Is taking or has ever taken pioglitazone or other Thiazolidinediones. * Has received or donated blood or blood products within 30 days preceding the Screening visit or plans to donate blood during the study.